Goodwill Impairment: The Deal's Verdict, Delivered Years Later

The Acquisition Is Re-Priced Every Year, Whether Anyone Wants It Re-Priced or Not

A transaction closes and the valuation work appears to end. The price was agreed, the bridge settled the consideration, the funds moved.

What actually happens is that the valuation moves from a negotiation into a reporting obligation.

The premium paid over the fair value of what was acquired sits on the balance sheet as goodwill. From the first reporting date onward it must be tested against whether the acquired business can still recover it, annually and on any indication of impairment.

The assumptions that justified the price become assumptions that have to keep holding. In public, in front of auditors, for as long as the goodwill remains.

This is the most under-appreciated consequence of an acquisition.

A price that required aggressive growth to justify hasn't been made safe by the counterparty accepting it. It's been converted into a carrying value that requires the same aggressive growth to survive an annual test.

That test is administered by people who weren't in the room. The verdict arrives years later, by a mechanism the acquirer doesn't control, in a document everybody reads.

This article sets out how that verdict is reached: where goodwill comes from, how the cash-generating unit is defined and why the level chosen often decides the outcome before any cash flow is forecast, the two permitted measures of recoverable amount, and the three assumptions carrying the weight.

It completes a series. The enterprise-to-equity bridge decides what a seller receives. The quality-of-earnings review decides what number the multiple was applied to. The impairment test decides, years later, whether the price was supportable.

Goodwill Is What Is Left When Everything Identifiable Has Been Recognised

Goodwill arises on a business combination as consideration transferred less the fair value of the identifiable net assets acquired. Every word is doing work.

Consideration includes contingent elements measured at fair value, not only cash paid at completion.

Identifiable net assets are measured at fair value on acquisition rather than carried across at book values. The exercise routinely recognises assets the seller never had on its own balance sheet: customer relationships, brands, technology, order backlogs.

Internally generated intangibles generally aren't recognised by the entity that generates them, but they are recognised by an acquirer who has paid for them.

The purchase price allocation is therefore consequential rather than administrative, and it's a valuation exercise in its own right.

The more of the price attributed to identifiable intangibles, the less remains as goodwill. But those intangibles are typically amortised over finite lives.

So the allocation trades a residual balance tested annually for a charge running through profit every year. Pushing value into goodwill defers cost and concentrates risk. Recognising more intangibles accepts a predictable drag for a smaller residual.

Where our valuation team performs a purchase price allocation, both consequences go to the board before it's finalised. The decision is often presented as technical when its effect on reported earnings for the next decade isn't.

What makes goodwill distinctive is that it can't be tested on its own.

It generates no cash flows independently of other assets. By construction it's the part of the price that couldn't be attributed to anything identifiable.

So the standards require it to be allocated to the cash-generating units expected to benefit from the synergies of the combination. It's the recoverable amount of those units, not of the goodwill, that gets tested.

The Level the Cash-Generating Unit Is Drawn At Frequently Decides the Answer

A cash-generating unit is the smallest identifiable group of assets generating cash inflows largely independent of other assets.

Goodwill is allocated to units, or groups of units, reflecting the level at which it's monitored internally, subject to a ceiling at the operating segment level.

Between the smallest independent unit and that ceiling there is judgement, and the judgement is decisive.

The mechanism is simple. Test a small unit, and the acquired business defends its own carrying value on its own cash flows, with no help.

Test a large group, and the acquisition is pooled with everything else, so headroom from unrelated successful operations can absorb the shortfall entirely.

The same acquisition, the same performance, the same forecasts can produce an impairment at one level and none at the other.

That isn't a loophole. It's a consequence of testing goodwill in the unit that benefits from the synergies. But it means the boundary is the first thing to examine, and it's examined too rarely.

In the mandates our advisers support, the CGU boundary is reconciled back to the allocation made at acquisition before any forecast is reviewed. A boundary that has moved since acquisition can mask an outcome the original allocation would have exposed.

Boundaries do legitimately move, so what deserves attention is the direction of travel. A reorganisation pooling an underperforming acquisition into a larger, healthier group has changed the test in the acquisition's favour.

Whether it reflects how the business is now actually managed is a question of fact, evidenced from internal reporting rather than debated in the abstract.

Our financial due diligence team asks for the internal management pack before the impairment memorandum. The pack shows how the business is monitored; the memorandum shows how it has been described for the test.

Value in Use and Fair Value Less Costs of Disposal Answer Different Questions

Recoverable amount is the higher of a unit's value in use and its fair value less costs of disposal.

An impairment arises where the carrying amount, including allocated goodwill, exceeds that recoverable amount.

Because the test takes the higher of the two, an entity needs only one to clear. Value in use is entity-specific: the present value of future cash flows from the unit as it stands.

Its defining constraint is that it's measured on the asset as it stands. Cash flows from a restructuring the entity isn't yet committed to, or from enhancing performance beyond current condition, are excluded.

Separating the cash flows of the asset as it is from the asset as management intends it to become is the substantive work. It's where our valuation team spends review time, not on the arithmetic of discounting.

Fair value less costs of disposal is a market measure: what a market participant would pay, less selling costs.

It isn't entity-specific, so it can include benefits a market participant would obtain that the current owner can't. But it must be supportable by market evidence rather than internal expectation.

Where recent comparable transactions exist, this measure can be more reliable than a discounted forecast. Where evidence is thin, a calculation labelled fair value that's really a discounted cash flow with a different rate won't withstand scrutiny.

The practical point is that the two fail in different conditions.

Value in use falls when the entity's own forecasts deteriorate. Fair value falls when market pricing for that kind of business deteriorates, which can happen while internal forecasts are unchanged.

Three Assumptions Carry the Weight, and One of Them Moves on Its Own

A value-in-use calculation has many inputs and three that matter: forecast cash flows, terminal growth rate, discount rate. Two are defended by management. The third is set by markets and moves on its own.

Prior forecasts and outturn both exist. A calculation assuming recovery to a level the unit forecast in each of the preceding three years and never reached asserts something its own records contradict.

In the mandates our advisers support, the first exhibit isn't a new forecast. It's a comparison of previous forecasts against outturn. Credibility established that way is worth more in the audit discussion than additional modelling.

The terminal growth rate is the quietest and frequently the most powerful.

Because terminal value typically dominates present value in a long-lived unit, a rate that looks conservative in isolation can carry an implausible implication: that the unit grows in perpetuity at a rate approaching the economy it operates in, eventually becoming an ever-larger share of it.

The discount rate is the one that moves on its own. It's why a test that passed comfortably can fail with no deterioration in the business.

Terminal value is the largest component of most calculations, and it's inversely sensitive to the gap between the discount rate and terminal growth. A modest increase compresses that gap and reduces recoverable amount disproportionately.

Where the two are close, the calculation is unstable by construction. Our valuation team runs the sensitivity as a grid rather than single-point movements, because it's the combination that produces the surprise.

Move the Assumptions and Watch the Headroom Disappear

The instrument below computes a recoverable amount from the three load-bearing assumptions and sets it against a carrying value, exactly as a value-in-use test does. It is seeded with an illustrative unit that passes its test with room to spare. The method is stated in full above the instrument, and the arithmetic is ordinary discounting — there is nothing proprietary in it.

The point of the exercise is not the headline figure but the fragility. Move the discount rate by a quarter of a point at a time and watch what happens to a buffer that looked comfortable. Then narrow the gap between the discount rate and the terminal growth rate and observe that the same movement produces a much larger effect. That instability is a property of the model, it is present in every long-lived unit tested this way, and it is why the sensitivity disclosures are read before the headroom figure by anyone who has done this work.

Non-Cash Does Not Mean Without Consequence

An impairment charge moves no cash, and it's frequently introduced on that basis. What that omits is that the charge is a disclosure, and disclosures are read by parties whose decisions do move cash.

But the charge is a statement by the borrower's own directors, supported by its auditors, that a unit isn't expected to recover its carrying amount.

Analysts read it as information about the forecasts, not the accounting. A charge tells them assumptions underpinning a previously supported carrying value have been revised downward, and invites the question of what else rests on the same assumptions.

In the mandates our transaction advisory practice runs, the disclosure is drafted alongside the calculation rather than after it. A defensible number and a sentence explaining it are two separate pieces of work, and only one is read by the market.

Boards should read it as the closing of a loop. The impairment test is the only mechanism in financial reporting that systematically compares an acquisition's thesis to its outcome, whether the board wishes to revisit the decision or not.

The most substantial cost of an impairment is usually the one that arrived before the charge did.

By the time a test fails, the shortfall it reflects has been evident internally for some time. The value was lost in the period the business underperformed, not on the day the accounting caught up.

That's why an impairment is better understood as a verdict than an event. It records a conclusion the facts reached earlier.

A Price Is Agreed Once and Defended Every Year After

The discipline this argues for isn't caution at acquisition for its own sake.

Businesses are worth paying for, premiums are frequently justified, and a board that never pays above the fair value of identifiable net assets will acquire very little.

What the impairment mechanism imposes is a consistency requirement across time. The assumptions used to justify the price are the assumptions that will be tested, by a process the acquirer doesn't control, in a document its appraisers and analysts will read.

The practical consequence is that assumptions relied on at acquisition should be recorded at acquisition, specific enough to be tested afterwards.

A growth rate, a margin trajectory, a synergy delivery schedule with dates against it. Written down while they're still a thesis, rather than reconstructed later from a model updated a dozen times.

Boards that do this find the annual test straightforward, because the comparison they're asked to make is one they've already been making.

Boards that don't find themselves defending a carrying value against a forecast whose relationship to the original case nobody can now establish.

Our valuation team asks for the acquisition case as the first document on any impairment engagement. Where it can't be produced in its original form, that is itself the most useful finding of the review.

This completes the series.

The quality-of-earnings review establishes what number the multiple should apply to. The enterprise-to-equity bridge determines what happens to the value that multiple produces. The impairment test re-marks the whole of it against what actually occurred.

The three are the same valuation question asked at three points in time, and the answers are supposed to agree. Where they don't, the disagreement is information, available to any board willing to run the test on itself before the auditors do.